Evaluation of the Role of Probiotics in Endodontic Treatment: A Preliminary Study.
Evaluation of the Role of Probiotics in Endodontic Treatment: A Preliminary Study.
复制标题
DOI：
10.4103/2231-0762.200710
复制
发表时间：
2017-01
影响因子：
1.1
通讯作者：
Kokate S
中科院分区：
文献类型：
--
作者：
Bohora A;Kokate S
根管治疗的主要目的是预防根尖周感染。急性和慢性根尖牙周炎的发生是由于病原微生物的持续存在，如粪肠球菌和白色念珠菌窝藏的根管系统的牙齿。使用益生菌治疗牙髓病是一个新的概念，尚未得到充分的研究。在益生菌在牙周治疗中取得成功的基础上，本研究进行了以下初步工作：（a）评价益生菌对常见牙髓致病菌，即大肠杆菌的抗菌效果; faecalis和C.白色念珠菌，和（B）评估益生菌疗法作为牙髓治疗程序中的添加剂的潜在用途。选择两种商业益生菌，并根据微生物的数量和浓度进行评价。致病性试验菌为C. albicans（ATCC 10231）和E.粪链球菌（ATCC 29212）。第一阶段采用琼脂杯法对筛选出的益生菌进行抑菌活性评价。faecalis和C.根据制造商的说明书分离来自益生菌样品的微生物。致病微生物设定为0.1麦克法兰标准挑战。在每个浇注板中冲压出直径为8 mm的圆形威尔斯孔。将适当稀释的供试品加入上述打孔的威尔斯孔中。向每个孔中加入的溶液体积为100 μl。将板在需氧条件下在37°C下直立孵育24小时。孵育后，测量ZOI（mm）。通过在试管中将9 ml 30%泊洛沙姆407和de Man，Rogosa and Sharpe（MRS）肉汤与500 μl E. faecalis或C. 252的光密度（OD），连同500 μ 1的测试益生菌菌株，设置在各自的OD。然后将样品在37°C下孵育48小时，随后以1 ml连续稀释至108。这样做是为了计算菌落形成单位（CFU）/ml计数。使用的对照是30%泊洛沙姆与MRS肉汤中的牙髓病原体，没有任何益生菌组。益生菌组对大肠杆菌有抑制作用。对粪肠杆菌无明显影响;白色念珠菌在生物膜阶段，两个测试组对病原生物体具有抗菌作用。这项研究表明，乳酸杆菌和双歧杆菌的益生菌生物是有效的，以防止大肠杆菌的生长。faecalis和C.体外培养白色念珠菌。由于益生菌有不同的成分和浓度，建议并保证进一步评估其在治疗牙髓感染中的作用。此外，该研究表明泊洛沙姆407可用作益生菌的理想递送载体，用作潜在的根管治疗根管内药物。
The principal goal of endodontics is the prevention of periapical infection. Acute and chronic apical periodontitis occur due to the persistence of pathogenic microorganisms such as Enterococcus faecalis and Candida albicans harboring the root canal systems of the teeth. The concept of the use of probiotics in addressing endodontic disease is new and has not been studied adequately. On the basis of the success of probiotics in periodontal treatment, this preliminary work was performed (a) to evaluate the antibacterial efficacy of probiotics against common endodontic pathogens, i.e. E. faecalis and C. albicans, and (b) to evaluate the potential use of probiotic therapy as an additive in endodontic treatment procedures. Two commercial probiotics were selected and evaluated based upon the numbers and concentration of organisms. Pathogenic test organisms were C. albicans (ATCC 10231) and E. faecalis (ATCC 29212). Phase 1 of the study was conducted by agar cup method test to evaluate the antibacterial activity of the selected probiotics against E. faecalis and C. albicans by measuring zones of inhibition (ZOI) in mm. Microorganisms from probiotic samples were isolated following manufacturer's instructions. Pathogenic organisms were set to a 0.1 McFarland standard challenge. Circular wells of 8 mm diameter were punched in each of the poured plates. Appropriately diluted test samples were added to the above-punched wells. The volume of the solution added to each well was 100 μl. The plates were incubated in an upright position at 37°C for 24 hours under aerobic conditions. Post incubation, ZOI was measured (mm). Phase 2 was conducted by mixing 9 ml of 30% poloxamer 407 and de Man, Rogosa and Sharpe (MRS) broth in a test tube with 500 μl of either E. faecalis or C. albicans set at an optical density (OD) of 0.252, together with 500 μl of test probiotic strain, set at a respective OD. Samples were then incubated at 37°C for 48 hours, followed by serial dilutions by 1 ml till 108. This was done to calculate colony forming units (CFU)/ml counts. Controls used were endodontic pathogens in 30% poloxamer with MRS broth without any probiotic group. Probiotic groups showed inhibitory activity against E. faecalis by the agar cup method, whereas there was no effect on C. albicans. In the biofilm stage, both the test groups had an antibacterial effect on pathogenic organisms. This study suggests that probiotic organisms of the species Lactobacillus and Bifidobacterium are effective for preventing the growth of E. faecalis and C. albicans in vitro. Because probiotics are available in varied compositions and concentrations, further evaluation for their role in treating endodontic infection is suggested and warranted. In addition, the study suggested that poloxamer 407 could be utilized as an ideal delivery vehicle for probiotics for use as a potential endodontic intracanal medicament.